Angiogenic and lymphangiogenic remodeling has long been accepted as a hallmark of cancer development and progression; however, the impacts of this remodeling on immunological responses, which are paramount to the responses to immunotherapeutic treatments, are underexplored. As immunotherapies represent one of the most promising new classes of cancer therapy, in this study, we explore the effects of angiogenic and lymphangiogenic normalization on dissemination of molecules injected into the tumor microenvironment to immune cells in lymph nodes draining the tumor as well as in systemically distributed tissues. A system of fluorescent tracers, size-matched to biomolecules of interest, was implemented to track different mechanisms of tumor transport and access to immune cells. This revealed that the presence of a tumor, and either angiogenic or lymphangiogenic remodeling, altered local retention of model biomolecules, trended toward normalizing dissemination to systemic organs, and modified access to lymph node-resident immune cells in manners dependent on mechanism of transport. More specifically, active cell migration by skin-derived antigen presenting cells was enhanced by both the presence of a tumor and lymphangiogenic normalization, while both angiogenic and lymphangiogenic normalization restored patterns of immune cell access to passively draining species. As a whole, this work uncovers the potential ramifications of tumor-induced angiogenesis and lymphangiogenesis, along with impacts of interrogation into these pathways, on access of tumor-derived species to immune cells.
Impact Statement
Angiogenic and lymphangiogenic normalization strategies have been utilized clinically to interrogate tumor vasculature with some success. In the age of immunotherapy, the impacts of these therapeutic interventions on immune remodeling are unclear. This work utilizes mouse models of angiogenic and lymphangiogenic normalization, along with a system of fluorescently tagged tracers, to uncover the impacts of angiogenesis and lymphangiogenesis on access of tumor-derived species to immune cell subsets within various organs.
Get full access to this article
View all access options for this article.
References
1.
SungH., FerlayJ., SiegelR.L., et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71, 209, 2021.
2.
HowlanderN., NooneA.M., KrapchoM., et al.. SEER Cancer Statistics Review, 1975–2016. Bethesda, MD: National Cancer Institute, 2019.
3.
ShieldsJ.D., BorsettiM., RigbyH., et al.Lymphatic density and metastatic spread in human malignant melanoma. Br J Cancer, 90, 693, 2004.
4.
SkobeM., HambergL.M., HawighorstT., et al.Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol, 159, 893, 2001.
5.
DadrasS.S., PaulT., BertonciniJ., et al.Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol, 162, 1951, 2003.
6.
LundA.W., WagnerM., FankhauserM., et al.Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest, 126, 3389, 2016.
7.
JonesD., PereiraE.R., and PaderaT.P.Growth and immune evasion of lymph node metastasis. Front Oncol, 8, 36, 2018.
8.
IyerA.K., KhaledG., FangJ., and MaedaH.Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today, 11, 812, 2006.
9.
PrabhakarU., MaedaH., JainR.K., et al.Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res, 73, 2412, 2013.
10.
TongR.T., BoucherY., KozinS.V., WinklerF., HicklinD.J., and JainR.K.Vascularization normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res, 64, 3731, 2004.
11.
WildiersH., GuetensG., De BoeckG., et al.Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer, 88, 1979, 2003.
12.
LiuQ., ZhangH., JiangX., QianC., LiuZ., and LuoD.Factors involved in cancer metastasis: a better understanding to “seed and soil” hypothesis. Mol Cancer, 16, 176, 2017.
13.
ChauhanV.P., MartinJ.D., LiuH., et al.Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun, 4, 2516, 2013.
14.
LiuJ., LiaoS., HuangY., et al.PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin Cancer Res, 17, 3638, 2011.
15.
GoelS., DudaD.G., XuL., et al.Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev, 91, 1071, 2011.
16.
ZhuA.X., FinnR.S., MulcahyM., et al.A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res, 19, 6614, 2013.
17.
LevinV.A., ChanJ., DattaM., YeeJ.L., and JainR.K.Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab. J Neurooncol, 134, 325, 2017.
18.
SorensenA.G., EmblemK.E., PolaskovaP., et al.Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res, 72, 402, 2012.
19.
KodackD.P., ChungE., YamashitaH., et al.Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc Natl Acad Sci U S A, 109, E3119, 2012.
20.
JainR.K.Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng, 1, 241, 1999.
21.
LinM., MaS.-P., LinH.-Z., JiP., XieD., and YuJ.-X.Intratumoral as well as peritumoral lymphatic vessel invasion correlates with lymph node metastasis and unfavourable outcome in colorectal cancer. Clin Exp Metastasis, 27, 123, 2010.
22.
KeslerC.T., LiaoS., MunnL.L., and PaderaT.P.Lymphatic vessels in health and disease. Wiley Interdiscip Rev Syst Biol Med, 5, 111, 2013.
23.
BonoP., WaseniusV.-M., HeikkilaP., LundinJ., JacksonD.G., and JoensuuH.High LYVE-1—positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Res, 10, 7144, 2004.
24.
HuangY., YuanJ., RighiE., et al.Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A, 109, 17561, 2012.
25.
PinterM., WeinmannA., WoM.-A., et al.Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. United Eur Gastroenterol J, 5, 987, 2017.
26.
ChauhanV.P., ChenI.X., TongR., et al.Reprogramming the microenvironment with tumorselective angiotensin blockers enhances cancer immunotherapy. Proc Natl Acad Sci U S A, 166, 10674, 2019.
27.
JainR.K., MartinJ.D., and StylianopoulosT.The role of mechanical forces in tumor growth and therapy. Annu Rev Biomed Eng, 16, 321, 2014.
28.
PetrovaT.V., and KohG.Y.Biological functions of lymphatic vessels. Science (80-), 369, eaax4063, 2020.
29.
AlishekevitzD., Gingis-VelitskiS., Kaidar-PersonO., et al.Macrophage-induced lymphangiogenesis and metastasis following paclitaxel chemotherapy is regulated by VEGFR3. Cell Rep, 17, 1344, 2016.
30.
CourauT., Nehar-BelaidD., FlorezL., et al.TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies. JCI Insight, 1, 1, 2016.
31.
PassarelliA., MannavolaF., StucciL.S., TucciM., and SilvestrisF.Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget, 8, 106132, 2017.
32.
HuangY., StylianopoulosT., DudaD.G., FukumuraD., and JainR.K.Benefits of vascular normalization are dose and time dependent-letter. Cancer Res, 73, 7144, 2013.
33.
TaubeJ.M., KleinA., BrahmerJ.R., et al.Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res, 20, 5064, 2014.
34.
ErdagG., SchaeferJ.T., SmolkinM.E., et al.Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res, 72, 1070, 2012.
35.
MarzagalliM., EbeltN.D., and ManuelE.R.Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin Cancer Biol, 59, 236, 2019.
36.
O'MeliaM.J., LundA.W., and ThomasS.N.The biophysics of lymphatic transport: engineering tools and immunological consequences. iScience, 22, 28, 2019.
37.
LaneR.S., FemelJ., BreazealeA.P., et al.IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med, 215, 3057, 2018.
38.
PaderaT.P., MeijerE.F.J., and MunnL.L.The lymphatic system in disease processes and cancer progression. Annu Rev Biomed Eng, 18, 125, 2016.
39.
ThomasS.N., RohnerN.A., and EdwardsE.E.Implications of lymphatic transport to lymph nodes in immunity and immunotherapy. Annu Rev Biomed Eng, 18, 207, 2016.
40.
PodgrabinskaS., KamaluO., MayerL., et al.Inflamed lymphatic endothelium suppresses dendritic cell maturation and function via Mac-1/ICAM-1-dependent mechanism. J Immunol, 183, 1767, 2009.
41.
HirosueS., VokaliE., RaghavanV.R., et al.Steady-state antigen scavenging, cross-presentation, and CD8+ T cell priming: a new role for lymphatic endothelial cells. J Immunol, 192, 5002, 2014.
42.
DieterichL.C., IkenbergK., CetintasT., KapaklikayaK., HutmacherC., and DetmarM.Tumor-associated lymphatic vessels upregulate PDL1 to inhibit T-cell activation. Front Immunol, 8, 66, 2017.
43.
TewaltE.F., CohenJ.N., RouhaniS.J., et al.Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood, 120, 4772, 2012.
44.
RohnerN.A., and ThomasS.N.Melanoma growth effects on molecular clearance from tumors and biodistribution into systemic tissues versus draining lymph nodes. J Control Release, 223, 99, 2016.
45.
O'MeliaM.J., RohnerN.A., ManspeakerM.P., FrancisD.M., KissickH.T., and ThomasS.N.Quality of CD8+ T cell immunity evoked in lymph nodes is compartmentalized by route of antigen transport and functional in tumor context. Sci Adv, 6, eabd7134, 2020.
46.
SixtM., KanazawaN., SelgM., et al.The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity, 22, 19, 2005.
47.
RoozendaalR., MempelT.R., PitcherL.A., et al.Conduits mediate transport of low-molecular-weight antigen to lymph node follicles. Immunity, 30, 264, 2009.
48.
KissenpfennigA., HenriS., DuboisB., et al.Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating langerhans cells. Immunity, 22, 643, 2005.
49.
KitanoM., YamazakiC., TakumiA., et al.Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node. Proc Natl Acad Sci U S A, 113, 1044, 2016.
50.
DuvallC.L., TaylorW.R., WeissD., and GuldbergR.E.Quantitative microcomputed tomography analysis of collateral vessel development after ischemic injury. Am J Physiol Heart Circ Physiol, 287, H302, 2004.
51.
MelderR.J., KoenigG.C., WitwerB.P., SafabakhshN., MunnL.L., and JainR.K.During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med, 2, 992, 1996.
52.
JainR.K.Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol, 31, 2205, 2013.
53.
FukumuraD., DudaD.G., MunnL.L., and JainR.K.Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation, 17, 206, 2010.
54.
HanahanD., and WeinbergR.A.Hallmarks of cancer: the next generation. Cell, 144, 646, 2011.
55.
PereiraE.R., JonesD., JungK., and PaderaT.P.The lymph node microenvironment and its role in the progression of metastatic cancer. Semin Cell Dev Biol, 38, 98, 2015.
56.
JonesD., WangZ., ChenI.X., et al.Solid stress impairs lymphocyte infiltration into lymph-node metastases. Nat Biomed Eng, 5, 1426, 2021.
57.
PereiraE.R., KedrinD., SeanoG., et al.Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science (80-), 359, 1403, 2018.
58.
ArcherP.A., SestitoL.F., ManspeakerM.P., et al.Quantitation of lymphatic transport mechanism and barrier influences on lymph node-resident leukocyte access to lymph-borne macromolecules and drug delivery systems. Drug Deliv Transl Res, 11, 2328, 2021.
59.
YoungE., MieleL., TuckerK.B., HuangM., WellsJ., and GuJ.-W.SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells. Cancer Biol Ther, 10, 703, 2010.
60.
LinE.Y., LiJ.-F., GnatovskiyL., et al.Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res, 66, 11238, 2006.
61.
ConnollyK.A., KuchrooM., VenkatA., et al.A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. Sci Transl Med, 6, eabg7836, 2021.
62.
FrancisD.M., ManspeakerM.P., SchudelA., et al.Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. Sci Transl Med, 12, eaay3575, 2020.
63.
O'MeliaM.J., ManspeakerM.P., and ThomasS.N.Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC. Cancer Immunol Immunother, 70, 2179, 2021.
64.
HarrellM.I., IritaniB.M., and RuddellA.Lymph node mapping in the mouse. J Immunol Methods, 332, 170, 2008.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
